CRBU Stock Analysis: Buy, Sell, or Hold?
CRBU - Caribou Biosciences, Inc. Common Stock
$1.57
0.07 (4.67%)
▲
5d:
+5.37%
30d:
-14.21%
90d:
-17.8%
BUY
MODERATE Confidence
Analysis Updated: Aug 4, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Get Alerted When CRBU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRBU shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CRBU shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRBU is currently trading at $1.57, which is considered slightly low relative to its 30-day fair value range of $1.55 to $1.84.
Technical Outlook: Technically, CRBU is in a strong uptrend. Immediate support is located at $1.43, while resistance sits at $1.67. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: CRBU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+664.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRBU is in a strong uptrend. Immediate support is located at $1.43, while resistance sits at $1.67. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: CRBU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+664.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.55 -
$1.84
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 664.3% below Wall St target ($12.00)
Trading Range Analysis
30-Day Trading Range
$1.55 -
$1.84
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.43
Resistance Level
$1.67
Current Trend
Strong Uptrend
Technical data as of
Aug 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.12
Wall Street Target
$12.00
(+664.3%)
Revenue Growth (YoY)
1.9%
Share & Embed Analysis
Last updated: August 04, 2026 5:50 PM ET
Data refreshes hourly during market hours. Next update: 6:50 PM
Data refreshes hourly during market hours. Next update: 6:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRBU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Barbara G Mcclung
SELL
6938 shares
2026-02-24
Ruhi Ahmad Khan
SELL
6938 shares
2026-02-24
Timothy P Kelly
SELL
3147 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
